FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:845-846 August 24, 2006 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Piccart-Gebhart, M. J. Related Article by Pritchard, K. I. PubMed Citation

To the Editor: The observation that adjuvant chemotherapy with cyclophosphamide, epirubicin, and fluorouracil (CEF) yielded survival results superior to those obtained with cyclophosphamide, methotrexate, and fluorouracil (CMF) in premenopausal women with stage 2 breast cancer led to widespread implementation of CEF chemotherapy in Canada.¹ Pritchard and colleagues (May 18 issue)² analyzed outcomes according to whether the primary tumor expressed human epidermal growth factor receptor type 2 (HER2) and concluded that amplification of the HER2 gene in breast-cancer cells is associated with clinical responsiveness to anthracycline-containing chemotherapy.² A more widely applicable conclusion, however, is that for the majority of premenopausal women . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.